JP5702306B2 - 糖尿病治療のための組成物及び方法 - Google Patents

糖尿病治療のための組成物及び方法 Download PDF

Info

Publication number
JP5702306B2
JP5702306B2 JP2011545487A JP2011545487A JP5702306B2 JP 5702306 B2 JP5702306 B2 JP 5702306B2 JP 2011545487 A JP2011545487 A JP 2011545487A JP 2011545487 A JP2011545487 A JP 2011545487A JP 5702306 B2 JP5702306 B2 JP 5702306B2
Authority
JP
Japan
Prior art keywords
diabetes
acid
gastrointestinal
present
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011545487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515163A5 (cg-RX-API-DMAC7.html
JP2012515163A (ja
Inventor
ジャージー・リスザード・ジュージク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biokier Inc
Original Assignee
Biokier Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokier Inc filed Critical Biokier Inc
Publication of JP2012515163A publication Critical patent/JP2012515163A/ja
Publication of JP2012515163A5 publication Critical patent/JP2012515163A5/ja
Application granted granted Critical
Publication of JP5702306B2 publication Critical patent/JP5702306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2011545487A 2009-01-12 2010-01-11 糖尿病治療のための組成物及び方法 Active JP5702306B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14395109P 2009-01-12 2009-01-12
US61/143,951 2009-01-12
US29377310P 2010-01-11 2010-01-11
PCT/US2010/020629 WO2010081079A2 (en) 2009-01-12 2010-01-11 Composition and method for treatment of diabetes
US61/293,773 2010-01-11

Publications (3)

Publication Number Publication Date
JP2012515163A JP2012515163A (ja) 2012-07-05
JP2012515163A5 JP2012515163A5 (cg-RX-API-DMAC7.html) 2013-02-14
JP5702306B2 true JP5702306B2 (ja) 2015-04-15

Family

ID=42317190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545487A Active JP5702306B2 (ja) 2009-01-12 2010-01-11 糖尿病治療のための組成物及び方法

Country Status (23)

Country Link
US (2) US8470885B2 (cg-RX-API-DMAC7.html)
EP (1) EP2376077B1 (cg-RX-API-DMAC7.html)
JP (1) JP5702306B2 (cg-RX-API-DMAC7.html)
KR (4) KR20170034928A (cg-RX-API-DMAC7.html)
CN (1) CN102355896A (cg-RX-API-DMAC7.html)
AU (1) AU2010203413B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1006145B8 (cg-RX-API-DMAC7.html)
CA (1) CA2748827C (cg-RX-API-DMAC7.html)
CL (1) CL2011001692A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119010T1 (cg-RX-API-DMAC7.html)
DK (1) DK2376077T3 (cg-RX-API-DMAC7.html)
EA (1) EA022631B1 (cg-RX-API-DMAC7.html)
ES (1) ES2628233T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170886T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034551T2 (cg-RX-API-DMAC7.html)
LT (1) LT2376077T (cg-RX-API-DMAC7.html)
MX (1) MX2011007393A (cg-RX-API-DMAC7.html)
PL (1) PL2376077T3 (cg-RX-API-DMAC7.html)
PT (1) PT2376077T (cg-RX-API-DMAC7.html)
RS (1) RS56054B1 (cg-RX-API-DMAC7.html)
SI (1) SI2376077T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700278T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010081079A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318663B2 (en) 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
US20220071895A1 (en) * 2009-01-12 2022-03-10 Biokier, Inc. Composition and method for treatment of diabetes
US20150224081A1 (en) * 2009-01-12 2015-08-13 Biokier, Inc. Composition and method for treatment of diabetes
WO2012161670A2 (en) 2010-04-07 2012-11-29 Incube Labs, Llc Method for treating diabetes and other glucose regulation disorders using stem cells
ES2705236T3 (es) 2010-05-12 2019-03-22 Univ Columbia Procedimientos para producir células enteroendocrinas que producen y secretan insulina
KR20140030171A (ko) * 2011-05-02 2014-03-11 바이오키어 인코포레이티드 당뇨병 치료를 위한 조성물 및 치료법
KR20130055220A (ko) 2011-11-18 2013-05-28 삼성전자주식회사 동박적층판 및 이를 사용한 금속코어기판의 제조방법
BR112014011898A2 (pt) * 2011-11-21 2017-05-16 Emmaus Medical Inc métodos e composições para o tratamento de diabetes e sintomas relacionados
US20150073057A1 (en) * 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
CA2985344A1 (en) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
EP4194001B1 (en) * 2015-04-22 2026-03-18 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment of type 2 diabetes and obesity
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
CN107684550B (zh) * 2016-08-03 2020-04-10 徐天宏 糖尿病治疗产品及其制备与应用
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019165309A1 (en) 2018-02-23 2019-08-29 Ambra Bioscience Llc Compositions and methods for hunger control and weight management
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US20210046011A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
US20230190686A1 (en) * 2021-12-17 2023-06-22 Biokier, Inc. Composition and method for treatment of diabetes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA885473B (en) * 1987-08-07 1989-03-29 Century Lab Inc Free fatty acids for treatment of diabetes mellitus
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
ES2234139T3 (es) 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid or bile salt fatty acids conjugates for the preparation of pharmaceutical compositions for reducing cholesterol, treating fatty liver and treating hyperglycemia and diabetes
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
US20030203004A1 (en) * 2002-04-24 2003-10-30 Kelm Gary Robert Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
PT1506963E (pt) 2003-10-28 2005-08-31 Adorkem Technology Spa Processo para a preparacao de citalopram
ITMI20040187A1 (it) 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
JP2006056881A (ja) 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
BRPI0609464A2 (pt) 2005-05-23 2010-04-13 Japan Tobacco Inc composto de pirazol e agente terapêutico para diabetes compreendendo o mesmo
DE102005046237A1 (de) 2005-09-28 2007-04-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
ITMI20052000A1 (it) * 2005-10-21 2007-04-22 Promefarm S R L Compressa gastroresitente a base di butirrato di sodio
CN101404987A (zh) 2006-01-20 2009-04-08 史密丝克莱恩比彻姆公司 磺酰胺衍生物在治疗代射和神经系统疾病中的用途
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
CA2673054C (en) * 2006-12-15 2016-05-10 Tima Foundation Novel compositions and uses thereof
EP2367554A4 (en) 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
US8318663B2 (en) 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
RU2505292C2 (ru) 2009-02-10 2014-01-27 Амарин Фармасьютикалз Айрлэнд Лимитед Способы лечения гипертриглицеридемии
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same

Also Published As

Publication number Publication date
WO2010081079A2 (en) 2010-07-15
LT2376077T (lt) 2017-08-10
US20130102581A1 (en) 2013-04-25
CA2748827A1 (en) 2010-07-15
AU2010203413A1 (en) 2011-07-14
ES2628233T3 (es) 2017-08-02
WO2010081079A3 (en) 2010-11-25
SMT201700278T1 (it) 2017-07-18
EA201190068A1 (ru) 2012-01-30
KR20170138573A (ko) 2017-12-15
BRPI1006145A2 (pt) 2017-05-30
BRPI1006145B8 (pt) 2021-05-25
US8470885B2 (en) 2013-06-25
US8680085B2 (en) 2014-03-25
RS56054B1 (sr) 2017-09-29
AU2010203413B2 (en) 2015-05-14
HRP20170886T1 (hr) 2017-09-08
PL2376077T3 (pl) 2017-10-31
KR20170034928A (ko) 2017-03-29
EA022631B1 (ru) 2016-02-29
EP2376077B1 (en) 2017-03-15
KR20190062609A (ko) 2019-06-05
JP2012515163A (ja) 2012-07-05
HUE034551T2 (en) 2018-02-28
PT2376077T (pt) 2017-06-23
SI2376077T1 (sl) 2017-09-29
DK2376077T3 (en) 2017-06-26
KR20110120866A (ko) 2011-11-04
CY1119010T1 (el) 2018-01-10
EP2376077A2 (en) 2011-10-19
EP2376077A4 (en) 2012-08-29
CN102355896A (zh) 2012-02-15
MX2011007393A (es) 2011-10-06
CL2011001692A1 (es) 2012-04-13
BRPI1006145B1 (pt) 2021-03-09
US20110275716A1 (en) 2011-11-10
CA2748827C (en) 2017-10-10

Similar Documents

Publication Publication Date Title
US8680085B2 (en) Composition and method for treatment of diabetes
AU2012250877B2 (en) Composition and method for treatment of diabetes
US9301938B2 (en) Composition and method for treatment of diabetes
US9006288B2 (en) Composition and method for treatment of diabetes
US20190262262A1 (en) Composition and method for treatment of diabetes
US20220387305A1 (en) Composition and method for treatment of diabetes
US20150224081A1 (en) Composition and method for treatment of diabetes
US20220071895A1 (en) Composition and method for treatment of diabetes
US20220054406A1 (en) Composition and method for treatment of diabetes
US20230149300A1 (en) Composition and method for treatment of diabetes
US20230133176A1 (en) Composition and method for treatment of diabetes
HK1195004A (en) Composition and method for treatment of diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140523

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141121

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150219

R150 Certificate of patent or registration of utility model

Ref document number: 5702306

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250